Critical Care Research and Practice / 2010 / Article / Tab 2

Case Report

Safety and Efficacy of Erythropoietin in Traumatic Brain Injury Patients: A Pilot Randomized Trial

Table 2

Daily NSE and S-100B levels by study group.

NSES-100B
DayEPOPlaceboEPOPlacebo

Admission34.4 (20.9)24.9 (21.0)0.087 (0.04)0.094 (0.05)
120.0 (9.9)16.4 (6.4)0.035 (0.01)0.041 (0.03)
220.3 (16.4)9.4 (4.0)0.025 (0.009)0.031 (0.02)
39.5 (10.5)7.8 (7.6)0.017 (0.006)0.016 (0.004)
48.9 (7.3)11.2 (13.4)0.016 (0.005)0.016 (0.004)
510.8 (9.2)4.1 (1.8)0.016 (0.005)0.016 (0.003)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.